The Effect of Food or Omeprazole on the Pharmacokinetics of Osimertinib in Patients With Non-Small-Cell Lung Cancer and in Healthy Volunteers-Reference-Cited by-同舟云学术

The Effect of Food or Omeprazole on the Pharmacokinetics of Osimertinib in Patients With Non-Small-Cell Lung Cancer and in Healthy Volunteers

Published:2017-11-26 Issue:4 Volume:58 Page:474-484
ISSN:0091-2700
Container-title:The Journal of Clinical Pharmacology
language:en
Short-container-title:The Journal of Clinical Pharmacology

Author:

Vishwanathan Karthick¹,Dickinson Paul A.²,Bui Khanh¹,Cassier Philippe A.³,Greystoke Alastair⁴,Lisbon Eleanor⁵,Moreno Victor⁶,So Karen⁷,Thomas Karen⁸,Weilert Doris⁵,Yap Timothy A.⁹¹⁰,Plummer Ruth⁴

Affiliation:

1. QCP, Early Clinical Development; IMED Biotech Unit; AstraZeneca; Waltham MA USA

2. Seda Pharmaceutical Development Services; The BioHub at Alderley Park; Alderley Edge Cheshire UK

3. Department of Medicine, Centre Léon Bérard; 28 Promenade Léa et Napoléon Bullukian; Lyon France

4. Northern Centre for Cancer Care, Freeman Hospital, Freeman Road; High Heaton; Newcastle upon Tyne UK

5. Quintiles IMS; Overland Park KS USA

6. START Madrid-FJD, Hospital Fundación Jimenez Díaz; Avenida Reyes Católicos 2; Madrid Spain

7. Oncology TMU, Early Clinical Development; AstraZeneca, Charter Way; Macclesfield UK

8. Karen Thomas Statistics Limited; 54 Pullman Lane; Godalming Surrey UK

9. Drug Development Unit; Royal Marsden NHS Foundation Trust; London UK

10. The Institute of Cancer Research; London UK

Funder

AstraZeneca, Cambridge, UK

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Reference25 articles.

1. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer;Cross;Cancer Discov,2014

2. Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study;Goss;Lancet Oncol,2016

3. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer;Jänne;N Engl J Med,2015

4. Ahn M-J;Mok;Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med,2017

5. Osimertinib in pretreated T790M-positive advanced non-small-cell lung cancer: AURA study phase II extension component;Yang;J Clin Oncol,2017

Cited by 46 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Proton pump inhibitors decrease efficacy of palbociclib in patients with metastatic breast;Journal of Oncology Pharmacy Practice;2024-08-02

2. Drug repurposing for cancer therapy;Signal Transduction and Targeted Therapy;2024-04-19

3. The effect of food on the pharmacokinetics of Sutetinib maleate capsule, an irreversible EGFR tyrosine kinase inhibitor, in healthy Chinese subjects;Investigational New Drugs;2024-04-11

4. Prognostic impact of concomitant pH-regulating drugs in patients with non-small cell lung cancer receiving epidermal growth factor receptor tyrosine kinase inhibitors: the Tokushukai REAl-world Data project 01-S1;Cancer Chemotherapy and Pharmacology;2024-04-08

5. Exploring inter-ethnic and inter-patient variability and optimal dosing of osimertinib: a physiologically based pharmacokinetic modeling approach;Frontiers in Pharmacology;2024-03-04